Werewolf Therapeutics (NASDAQ:HOWL) Issues Earnings Results

Werewolf Therapeutics (NASDAQ:HOWL) announced its earnings results on Friday. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.14, FiscalAI reports.

Werewolf Therapeutics Trading Down 9.5%

NASDAQ:HOWL opened at $0.78 on Friday. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87. The firm has a market capitalization of $37.90 million, a price-to-earnings ratio of -0.57 and a beta of 0.78. Werewolf Therapeutics has a one year low of $0.53 and a one year high of $2.38. The business has a fifty day moving average price of $0.69 and a 200-day moving average price of $1.03.

Insider Buying and Selling

In related news, Director Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock in a transaction on Monday, December 29th. The stock was sold at an average price of $0.61, for a total transaction of $66,249.66. Following the transaction, the director directly owned 2,550,674 shares in the company, valued at approximately $1,555,911.14. The trade was a 4.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders sold 499,420 shares of company stock valued at $296,825. 23.60% of the stock is currently owned by company insiders.

Institutional Trading of Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Susquehanna International Group LLP raised its stake in shares of Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after buying an additional 13,439 shares during the period. Vontobel Holding Ltd. grew its stake in shares of Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after acquiring an additional 24,003 shares during the period. Regal Investment Advisors LLC increased its holdings in Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares in the last quarter. Bank of America Corp DE increased its holdings in Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares in the last quarter. Finally, Qube Research & Technologies Ltd bought a new stake in Werewolf Therapeutics during the 2nd quarter worth approximately $48,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Analysts Set New Price Targets

HOWL has been the subject of several research analyst reports. Wedbush lowered Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective for the company. in a report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, January 21st. Citizens Jmp cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Citigroup downgraded Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. Finally, HC Wainwright lowered their price objective on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, December 19th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.